Biotech stocks facing FDA Decision in June

2 / 9

The FDA is expected to announce its decision regarding scPharmaceuticals Inc.’s (SCPH) Furoscix on June 23, 2018.

Furoscix is a drug-device combination product consisting of a proprietary Furosemide solution formulated to a neutral pH to allow for subcutaneous infusion via a patented Infusor, a wearable, pre-programed drug delivery system that is applied to the abdomen for subcutaneous drug administration.

The Company is seeking approval of Furoscix for the treatment of edema, or fluid overload, in patients with heart failure.

If approved, Furoscix will provide an alternative to intravenous (IV) and oral Furosemide for the treatment of worsening heart failure due to edema that would typically require hospitalization.

Leerink analyst Ami Fadia expects Furoscix to bring in sales of more than $600 million by 2025.

SCPH closed Friday’s (May 25) trading at $13.98, up 0.14%.